Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Vimeo has disclosed that data belonging to some of its customers and users has been accessed without authorization following the recent breach at the Anodot data anomaly detection company. The video ...
Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...
Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS ...
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...
The 2026 NFL Draft is over, and now it's all about analyzing each pick and how they fit. The Washington Commanders selected six players in the 2026 draft, beginning with Ohio State linebacker Sonny ...
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...
Hosted on MSN
Mind bending challenges anyone can try for fun
Mind bending challenges that anyone can try for fun and creativity CNN's Jake Tapper calls out Trump's latest 'deranged' and 'potentially dangerous' attack Ronda Rousey stops Gina Carano with an ...
Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...
Progressives push for a moratorium on new construction. Paul Gigot, Kim Strassel, Allyssia Finley, and Jason Riley discuss the growing progressive backlash against AI data centers. Citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results